Michael Hedenus
Overview
Explore the profile of Michael Hedenus including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
21
Citations
400
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Pirker R, Hedenus M, Vansteenkiste J, Hernandez E, Belton L, Terwey J
Clin Ther
. 2016 Jan;
38(1):122-135.e6.
PMID: 26730453
Purpose: Limited data are available to describe the effectiveness of darbepoetin alfa (DA) in terms of hemoglobin (Hb) and transfusion outcomes when initiated at Hb ≤10 g/dL (the threshold specified...
2.
Jaeger U, Trneny M, Melzer H, Praxmarer M, Nawarawong W, Yehuda D, et al.
Haematologica
. 2015 Apr;
100(7):955-63.
PMID: 25911553
We investigated rituximab maintenance therapy in patients with diffuse large B-cell lymphoma (n=662) or follicular lymphoma grade 3b (n=21) in first complete remission. Patients were randomized to rituximab maintenance (n=338)...
3.
Rampton D, Folkersen J, Fishbane S, Hedenus M, Howaldt S, Locatelli F, et al.
Haematologica
. 2014 Nov;
99(11):1671-6.
PMID: 25420283
Intravenous iron is widely used for the treatment of iron deficiency anemia when oral iron is inappropriate, ineffective or poorly tolerated. Acute hypersensitivity reactions during iron infusions are very rare...
4.
Hedenus M, Karlsson T, Ludwig H, Rzychon B, Felder M, Roubert B, et al.
Med Oncol
. 2014 Nov;
31(12):302.
PMID: 25373320
This randomized trial evaluated ferric carboxymaltose without erythropoiesis-stimulating agents (ESA) for correction of anemia in cancer patients with functional iron deficiency. Patients on treatment for indolent lymphoid malignancies, who had...
5.
Hedenus M, Ludwig H, Henry D, Gasal E
Cancer Med
. 2014 Jun;
3(5):1416-29.
PMID: 24890561
Pharmacovigilance (PV) is the science and activities relating to the detection, assessment, understanding, and prevention of adverse effects or other problems related to medical products after they have been licensed...
6.
Favrat B, Balck K, Breymann C, Hedenus M, Keller T, Mezzacasa A, et al.
PLoS One
. 2014 Apr;
9(4):e94217.
PMID: 24751822
Background: Unexplained fatigue is often left untreated or treated with antidepressants. This randomized, placebo-controlled, single-blinded study evaluated the efficacy and tolerability of single-dose intravenous ferric carboxymaltose (FCM) in iron-deficient, premenopausal...
7.
Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M
Curr Med Res Opin
. 2013 Jan;
29(4):325-37.
PMID: 23323876
Background: Prior to the approval of the first erythropoiesis-stimulating agent (ESA) in the early 1990s, red blood cell transfusions were the primary means of treating severe chemotherapy-induced anemia (CIA), with...
8.
Hedenus M, Osterborg A, Tomita D, Bohac C, Coiffier B
Leuk Lymphoma
. 2012 Apr;
53(11):2151-8.
PMID: 22497574
Erythropoiesis-stimulating agents (ESAs) are approved to treat anemia in patients with non-myeloid malignancies receiving myelosuppressive chemotherapy. ESAs reduce transfusion rates, but some clinical studies suggest that ESAs may reduce survival...
9.
Canon J, Vansteenkiste J, Hedenus M, Gascon P, Bokemeyer C, Ludwig H, et al.
Med Oncol
. 2011 Nov;
29(3):2291-9.
PMID: 22081263
Darbepoetin alfa (DA) is an erythropoiesis-stimulating agent (ESA) approved for treating chemotherapy-induced anemia (CIA). Safety concerns have prompted changes to the ESA-product information, which now recommends initiating ESAs at hemoglobin...
10.
Aapro M, Beguin Y, Birgegard G, Gascon P, Hedenus M, Osterborg A
J Clin Oncol
. 2011 May;
29(17):e525-6.
PMID: 21537041
No abstract available.